Last updated: 2026-10-16 22:53:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Harmony Biosciences Holdings, Inc. (HRMY) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $37.95, with a market capitalisation of $2.18B and a P/E ratio of 12.29. Over the past 52 weeks, its price has ranged from $25.52 to $43.49. This page covers its latest market performance, valuation, price trends and company information.
$2.18B | |
$38.47 | |
$62.09 | |
$18.61 | |
$38.27 | |
740.20K | |
897.66K | |
12.29 | |
$43.49 | |
$25.52 | |
-- | |
-- |
Harmony Biosciences Holdings, Inc. (HRMY) is trading at $37.97 in after-hours trading as of 2026-10-16 22:19:00, down 0.80% ($0.30) from the regular-session close of $38.27.
After-hours trading shows how investors are pricing HRMY after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Harmony Biosciences Holdings, Inc. (HRMY) moved from $39.34 to $37.95, representing a decline of 3.53% ($1.39).
The stock traded between $35.99 and $40.57 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 891.02 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 69.2%
HRMY is currently trading at $37.95, placing it 69.2% of the way from its 52-week low of $25.52 to its 52-week high of $43.49. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 293 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Harmony Biosciences Holdings, Inc. (HRMY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.